AbCheck discovers and
optimizes human therapeutic antibodies with one of
the industry’s most versatile technology platforms.
Tailored to specific needs and desired Target Product
Profiles, AbCheck leverages both cutting-edge (e.g.,
microfluidics, rabbit mass humanization) and state-of-the-art
(e.g., phage/yeast display libraries) technologies to
provide high quality leads. The company has proven its
capabilities in multiple partnerships throughout the US
and Europe. AbCheck is a wholly-owned subsidiary of
Ampersand Biomedicines, a Flagship Pioneering Company.